Explore the words cloud of the SHIGETECVAX project. It provides you a very rough idea of what is the project "SHIGETECVAX" about.
The following table provides information about the project.
EUROPEAN VACCINE INITIATIVE EWIV
|Coordinator Country||Germany [DE]|
|Total cost||0 €|
|EC max contribution||8˙603˙989 € (0%)|
1. H2020-EU.3.1.3. (Treating and managing disease)
|Duration (year-month-day)||from 2019-09-01 to 2024-08-31|
Take a look of project's partnership.
|1||EUROPEAN VACCINE INITIATIVE EWIV||DE (HEIDELBERG)||coordinator||359˙755.00|
|2||EVELIQURE BIOTECHNOLOGIES GMBH||AT (WIEN)||participant||5˙024˙401.00|
|3||INTERNATIONAL CENTRE FOR DIARRHOEAL DISEASE RESEARCH BANGLADESH||BD (DHAKA)||participant||1˙924˙713.00|
|4||GOETEBORGS UNIVERSITET||SE (GOETEBORG)||participant||749˙842.00|
Although vaccination is an effective way to reduce the huge disease burden associated with diarrhoea caused by enteric pathogens, many attempts to develop vaccines for shigellosis and ETEC infections have failed and a number of current approaches are too complex and costly to provide an adequate solution for LMICs. This Consortium is dedicated to advancing a radically new approach against Shigella and ETEC based not on the immunodominant, but highly variable Shigella LPS O-antigen, target of almost all past and current vaccine development efforts. There are four pillars on which the ShigETEC vaccine has been designed: (i) Elimination of the LPS O-antigen to allow recognition of multiple antigens on the cell surface that are shared among different serotypes of Shigella and are increasingly being recognized as important in protection from shigellosis. These antigens are also closely related to those of ETEC and may also help in protecting against that pathogen as well. (ii) Elimination of the invasiveness of Shigella by disruption of the invasion complex resulting in a much safer/less reactogenic oral vaccine that can take advantage of gut mucosal immunity, possibly allowing administration of high vaccine doses and therefore addresses the low immunogenicity seen with other live attenuated vaccine candidates. (iii) Addition of detoxified toxin antigens of ETEC that will induce neutralizing/blocking antibodies to these critical virulence factors. (iv) Rational molecular design of ShigETEC will allow future generations of vaccines to include additional antigens for other pathogens. The work programme entails manufacture of clinical trial material, first-in-human testing for safety and immunogenicity in non-endemic adults, a sero-epidemiology study to learn about natural immune response to the vaccine, and importantly testing the vaccine in endemic populations. The Consortium comprises partners from EU and Bangladesh that bring along highly complementary expertise.
Are you the coordinator (or a participant) of this project? Plaese send me more information about the "SHIGETECVAX" project.
For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.
Send me an email (email@example.com) and I put them in your project's page as son as possible.
Thanks. And then put a link of this page into your project's website.
The information about "SHIGETECVAX" are provided by the European Opendata Portal: CORDIS opendata.
PanCareFollowUp: Novel, patient-centred survivorship care to improve care quality, effectiveness, cost-effectiveness and accessibility for survivors and caregiversRead More
CeLac and European consortium for a personalized medicine approach to Gastric CancerRead More
Host-targeted Approaches for the Prevention and the treatment of Hospital-Acquired PneumoniaRead More